[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"total-gastrectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:total-gastrectomy":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100552121",false,"NCT06468969","Enhanced vs. Routine Follow-Up After Total Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial","A Prospective, Single-Center, Randomized Controlled Trial Comparing Enhanced Follow-up With Standard Follow-up in Post-Gastrectomy Patients With Advanced Gastric Cancer","Inclusion Criteria:\n\n* Age: 18 to 72 years at the time of informed consent.\n* Underwent radical total gastrectomy.\n* Postoperative pathology confirmed advanced adenocarcinoma of the stomach or gastroesophageal junction.\n* Estimated survival time ≥3 months.\n* Good cognitive and reading abilities, capable of completing questionnaires.\n* Willing and able to provide written informed consent for the study.\n\nExclusion Criteria:\n\n* Participation in another clinical trial within 4 weeks prior to enrollment.\n* Patients with other malignancies.\n* Clinically significant cardiovascular disease, such as heart failure (NYHA III-IV), uncontrolled coronary artery disease, cardiomyopathy, arrhythmia, or hypertension.\n* Neurological or psychiatric disorders affecting cognitive function, including central nervous system metastasis.\n* Active infectious diseases, such as active hepatitis or tuberculosis.\n* Uncontrolled systemic diseases, such as poorly controlled diabetes.\n* Interstitial lung disease, such as interstitial pneumonia, pulmonary fibrosis, or evidence of interstitial lung disease on baseline chest X-ray\u002FCT.\n* Pregnant or breastfeeding.","ALL","18 Years","72 Years",{"count":19,"type":20},158,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to compare the effectiveness of enhanced follow-up with standard follow-up in postoperative patients with advanced gastric cancer who have undergone radical gastrectomy. The main questions it aims to answer are:\n\nCan enhanced follow-up alleviate symptom burden and improve quality of life? What is the impact of enhanced follow-up on overall survival rates at 3 and 5 years post-surgery?\n\nParticipants will:\n\nBe randomly assigned to either the enhanced follow-up group or the standard follow-up group.\n\nUndergo comprehensive symptom, nutritional, and psychological assessments every 3 weeks (enhanced follow-up group).\n\nReceive routine postoperative follow-up including medical examinations and treatments as needed, with additional assessments only when necessary (standard follow-up group).\n\nResearchers will compare the enhanced follow-up group with the standard follow-up group to see if enhanced follow-up can improve quality of life and increase overall survival rates at 3 and 5 years post-surgery.\n\nOutcomes will be measured using the EORTC QLQ-C30 quality of life questionnaire and overall survival rates. This prospective, single-center, randomized controlled clinical trial will span 5 years from the approval by the institutional ethics committee and will include 158 patients.",[26,27,28,29,30],"Gastric Cancer","Total Gastrectomy","Postoperative Care","Quality of Life","Follow-up","NOT_YET_RECRUITING","2024-06-16",{"date":34,"type":35},"2024-06-21","ACTUAL",{"date":37,"type":20},"2024-07-01",{"date":39,"type":20},"2029-07-01",{"name":41,"class":42},"Fudan University","OTHER",""]